Comparison of survival for metastatic pancreatic cancer patients treated with CPI‐613 versus resected borderline‐resectable pancreatic cancer patients

Abstract

IntroductionTreatment of advanced pancreatic adenocarcinoma remains suboptimal. Therapeutic agents with a novel mechanism of action are desperately needed; one such novel agent is CPI‐613 targets. We here analyze the outcomes of 20 metastatic pancreatic cancer patients treated with CPI‐613 and FOLFIRINOX in our institution and evaluate their outcomes to borderline‐resectable patients treated with curative surgery.MethodsA post hoc analysis was performed of the phase I CPI‐613 trial data (NCT03504423) comparing survival outcomes to borderline‐resectable cases treated with curative resection at the same institution. Survival was measured by overall survival (OS) for all study cases and disease‐free survival (DFS) for resected cases with progression‐free survival for CPI‐613 cases.ResultsThere were 20 patients in the CPI‐613 cohort and 60 patients in the surgical cohort. Median follow‐up times were 441 and 517 days for CPI‐613 and resected cases, respectively. There was no difference in survival times between CPI‐613 and resected cases with a mean OS of 1.8 versus 1.9 year (p = 0.779) and mean PFS/DFS of 1.4 versus 1.7 years (p = 0.512). There was also no difference in 3‐year survival rates for OS (hazard ratio [HR] = 1.063, 95% confidence interval [CI] 0.302–3.744, p = 0.925) or DFS/PFS (HR = 1.462, 95% CI 0.285–7.505, p = 0.648).ConclusionThe first study to evaluate the survival between metastatic patients treated with CPI‐613 versus borderline‐resectable cases undergoing curative resection. Analysis revealed no significant differences in survival outcomes between the cohorts. Study results are suggestive that there may be potential utility with the addition of CPI‐613 to potentially resectable pancreatic adenocarcinoma, although additional research with more comparable study groups are required.